JP2018516937A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516937A5
JP2018516937A5 JP2017562994A JP2017562994A JP2018516937A5 JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5 JP 2017562994 A JP2017562994 A JP 2017562994A JP 2017562994 A JP2017562994 A JP 2017562994A JP 2018516937 A5 JP2018516937 A5 JP 2018516937A5
Authority
JP
Japan
Prior art keywords
pain
composition
item
eudragit
constipation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017562994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516937A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035886 external-priority patent/WO2016197042A1/en
Publication of JP2018516937A publication Critical patent/JP2018516937A/ja
Publication of JP2018516937A5 publication Critical patent/JP2018516937A5/ja
Pending legal-status Critical Current

Links

JP2017562994A 2015-06-05 2016-06-03 リナクロチドの改変または標的放出製剤 Pending JP2018516937A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562171462P 2015-06-05 2015-06-05
US62/171,462 2015-06-05
US201662339462P 2016-05-20 2016-05-20
US62/339,462 2016-05-20
PCT/US2016/035886 WO2016197042A1 (en) 2015-06-05 2016-06-03 Modified or targeted release formulations of linaclotide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020166911A Division JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤

Publications (2)

Publication Number Publication Date
JP2018516937A JP2018516937A (ja) 2018-06-28
JP2018516937A5 true JP2018516937A5 (cg-RX-API-DMAC7.html) 2019-07-04

Family

ID=56133109

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017562994A Pending JP2018516937A (ja) 2015-06-05 2016-06-03 リナクロチドの改変または標的放出製剤
JP2020166911A Withdrawn JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤
JP2022164508A Withdrawn JP2022179727A (ja) 2015-06-05 2022-10-13 リナクロチドの改変または標的放出製剤
JP2024140831A Pending JP2024161048A (ja) 2015-06-05 2024-08-22 リナクロチドの改変または標的放出製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020166911A Withdrawn JP2021001223A (ja) 2015-06-05 2020-10-01 リナクロチドの改変または標的放出製剤
JP2022164508A Withdrawn JP2022179727A (ja) 2015-06-05 2022-10-13 リナクロチドの改変または標的放出製剤
JP2024140831A Pending JP2024161048A (ja) 2015-06-05 2024-08-22 リナクロチドの改変または標的放出製剤

Country Status (5)

Country Link
US (2) US20190350863A1 (cg-RX-API-DMAC7.html)
EP (1) EP3302440B1 (cg-RX-API-DMAC7.html)
JP (4) JP2018516937A (cg-RX-API-DMAC7.html)
ES (1) ES2868873T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016197042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119191A1 (en) * 2016-12-21 2018-06-28 Ironwood Pharmaceuticals Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
CN114206324A (zh) * 2019-06-10 2022-03-18 硬木药品公司 治疗与腹泻占主导的肠易激综合征相关的腹部疼痛
US20230226143A1 (en) * 2020-06-30 2023-07-20 Ocvirk, Soren Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193801A1 (en) * 2008-08-15 2013-10-30 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
ES2608050T3 (es) * 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US20140005128A1 (en) * 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
JP5553132B2 (ja) * 2011-09-30 2014-07-16 アステラス製薬株式会社 粒子状医薬組成物
UA119335C2 (uk) * 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням

Similar Documents

Publication Publication Date Title
JP5968300B2 (ja) 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
US20240293327A1 (en) Monolithic tablets based on carboxyl polymeric complexes for controlled drug release
KR101799625B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
KR101799624B1 (ko) 제약 또는 기능식품 투여 형태에 적합한 코팅 조성물
El-Zahaby et al. Formulation and in vitro evaluation of size expanding gastro-retentive systems of levofloxacin hemihydrate
KR101767288B1 (ko) 복용 용이성 고형 제제
JP2017504590A5 (cg-RX-API-DMAC7.html)
HRP20231699T1 (hr) Formulacije inhibitora amorfne kinaze i postupci njihove primjene
JP6768070B2 (ja) 粘膜付着性医薬組成物及びその製造方法
CN103269691A (zh) 用于控制释放美沙拉嗪的口服药物片剂和其获得方法
TWI688411B (zh) 腸溶錠
JP2018516937A5 (cg-RX-API-DMAC7.html)
Iswandana et al. Preparation of calcium alginate-tetrandrine beads using ionic gelation method as colon-targeted dosage form
Ramli et al. Coatless alginate pellets as sustained-release drug carrier for inflammatory bowel disease treatment
CN110475557B (zh) 固体分散体
Segale et al. Calcium alginate multi-unit oral dosage form for delayed release of celecoxib
CN105078997A (zh) 一种利伐沙班药用组合物及其制备方法
Kim et al. Preparation of hydroxypropylmethyl cellulose-based porous matrix for gastroretentive delivery of gabapentin using the freeze-drying method
CN118234489A (zh) 吡啶酮衍生物的口服制剂及其在肠纤维化的预防和/或治疗中的用途
Tiwari et al. Enhancement of site specific delivery of diloxanide furoate as an antiamoebic drug
Patil et al. Development and Evaluation of Mesalamine Tablet Formulation for Colon Delivery
CA3060026A1 (en) Polymer based formulation for release of drugs and bioactives at specific git sites
Raffin et al. Pantoprazole sodium-loaded controlled release microparticles prepared by spray drying
Chauhan et al. Studies on colon targeted drug delivery system for Tinidazole in the treatment of amoebiasis
RU2696870C2 (ru) Пероральный препарат с замедленным высвобождением